Pharmafile Logo
Pharmafocus logo
Advanced Search
shutterstock_168864905

Ipsen shells out $1.31bn to acquire rare disease specialist Clementia Pharmaceuticals

February 25, 2019
Sales and Marketing Clementia pharmaceuticals, acquisition, ipsen, rare disease

In a bid to boost its rare disease portfolio prospects, Ipsen has revealed its intention to acquire Clementia Pharmaceuticals, with …

News
cocaine

UK launches drug testing service for illicit drugs

February 25, 2019
Sales and Marketing Home office, UK, cocaine, drugs, fentanyl, illicit substances, recreational drugs

The UK Home Office have licensed a drug-checking service for users of illicit substances. The yearlong pilot project, run by …

News
johnson_and_johnson_jj

Missouri Supreme Court ruling could help J&J in talc cases

February 25, 2019
Sales and Marketing Cancer, J&J, JJ, asbestos, baby powder, lawsuits, legal, talc

The Missouri Supreme Court has ruled that the practice of combining two or more cases in order to allow courts …

News

Roche set to acquire Spark Therapeutics in $4.8 billion deal

February 25, 2019
Sales and Marketing Roche, Spark Therapeutics, acquisition, gene therapy, pharma

Roche is set to fully acquire gene therapy Spark Therapeutics after entering into a definitive merger agreement, after the Boards …

News
iran

Iran ready to export medicines to Venezuela

February 25, 2019
Sales and Marketing FDA, Iran, Venezuela, biotech, global, pharma

The chairman of the Iranian Food and Drug Administration (FDA) Mehdi Pirsalehi, has said that Iran is ready to export …

News
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

February 22, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Cancer, China, MedImmune, Xeljanz, asthma, diabetes, keytruda, osteoarthritis, pharma, rare disease

Happy Friday! With the weekend within reach, check out our run-down of the top ten most popular articles on Pharmafile.com …

News

US Department of Justice investigate J&J over Baby Powder allegations

February 22, 2019
Medical Communications Cancer, J&J, JJ, Johnson and Johnson, USA, asbestos, oncology, talc

The Justice Department and US Securities and Exchanges Commission are investigation healthcare giant Johnson & Johnson over allegations that Johnson’s …

News
img_4190-e1376666350337-web

MHRA warns of congenital malformation risk of neo-mercazole during pregnancy

February 22, 2019
Medical Communications, Research and Development MHRA, neo-mercazole, pharma

UK drug watchdog The Medicines and Healthcare products Regulatory Agency (MHRA) has warned of the potential side-effects of Neo-mercazole (carbimazole) …

News

Genetically modified twins may have been altered in a way that improves memory and cognition

February 22, 2019
Medical Communications CCR5, HIV, cognitive enhancement, crispr, gene editing

The twins who were genetically modified using the gene editing tool CRISPR may have been changed in a way that …

News

Poison control calls for kratom increase from one a month to two a day, study shows

February 22, 2019
Medical Communications USA, herbal medicines, kratom, poison control, toxicology

The number of phone calls to US poison control centres over exposures to kratom – an herbal drug with opioid …

News

FDA halts Xencor’s acute myeloid leukaemia trial following two patient deaths

February 21, 2019
Research and Development Cancer, FDA, Xencor, leukaemia, pharma

Cancer biopharma firm Xencor has revealed it is to place a hold on its ongoing Phase 1 trial of XmAb14045, …

News
facilities_lg06

Indivior launches authorised generic version of opioid addiction treatment Suboxone as rival generic drugmakers enter market

February 21, 2019
Sales and Marketing Alvogen, Dr Reddy's, Novartis, Sandoz, indivior

Indivior has announced the launch of an authorised generic version of Suboxone Film (buprenorphine/naloxone) a combination medicine used to treat …

News

Pfizer overhauls Xeljanz study over concerns of increased risk of pulmonary embolism and death

February 21, 2019
Research and Development Pfizer, Xeljanz, pharma, rheumatoid arthritis

Pfizer is set to overhaul the dosing groups in its ongoing study of Xeljanz (tofacitinib) after an evaluation from a …

News

Teva settles ‘pay-to-delay’ case with FTC

February 21, 2019
Business Services, Sales and Marketing FTC, Teva, antitrust, drugs, generics, monopoly

Teva Pharmaceuticals has settled a dispute with the Federal Trade Commission (FTC) over three separate federal court antitrust lawsuits involving …

News
040424_026_avonmouth

Avara Avlon falls into administration putting 270 Bristol jobs at risk

February 21, 2019
Manufacturing and Production AstraZeneca, Avara Avlon, Bristol, CDMO, Jobs, UK, manufacturing

Bristol-based pharma firm Avara Avlon Pharmaceuticals has fallen into administration putting the jobs of all 270 of its staff at …

News
shutterstock_159488225

Intercept’s NASH liver fibrosis drug shows promise at Phase 3

February 20, 2019
Research and Development Intercept Pharmaceuticals, nash, non-alcoholic steatohepatitis, ocaliva, pharma

Intercept Pharmaceuticals has publicised promising new data on the efficacy of Ocaliva (obeticholic acid) in the treatment of liver fibrosis …

News
francesa

FDA approves Indian firm Alembic’s generic of Teva’s Diamox

February 20, 2019
Research and Development ANDA, Alembic, Gujurat, US FDA, diamox, generics

The US FDA has approved Guajarati firm Alembic Pharmaceuticals generic version of Teva’s Acetazolamide sold under the brand name Diamox, …

News

Pfizer and Eli Lilly’s chronic low back pain (CLBP) treatment meets primary endpoint in Phase 3 trial

February 20, 2019
Research and Development

US firms Pfizer and Eli Lilly have said that NGF inhibitor tanezumab met its primary endpoint in a phase 3 …

News
european_commission_web_5

Poland and Slovenia included in US-EU mutual recognition agreement

February 20, 2019
Research and Development EU, GMP, Poland, Slovenia, USA, mutual recognition

Poland and Slovenia have been deemed capable of carrying out Good Manufacturing Practice (GMP) inspections at an equivalent level to …

News
merckwindow_web

Keytruda falls short at Phase 3 in advanced liver cancer

February 20, 2019
Research and Development Cancer, MSD, keytruda, liver cancer, pharma

MSD has revealed new Phase 3 data which indicates that its blockbuster immunotherapy Keytruda (pembrolizumab), in combination with best supportive …

News
The Gateway to Local Adoption Series

Latest content

Historic UN declaration supporting mental health – treatment to be given similar priority to chronic diseases

January 30, 2026

Rare diseases – spinal muscular atrophy

January 30, 2026

Could targeting the molecular causes of infertility finally transform IVF success rates?

January 29, 2026

Digital mental health technologies – a valuable tool in supporting people with depression and anxiety

January 29, 2026

Barts Health NHS Trust collaborates with H.I.G. Realty on healthcare innovation building

January 29, 2026